Boehringer deal, clinical milestones support Bridge IPO

Deal with Boehringer, pending first-in-class readouts help Bridge raise $36M in KOSDAQ IPO

A big pharma deal and near-term clinical milestones provided enough grist for investors to back Bridge Biotherapeutics' IPO despite several recent setbacks for public Korean biotechs.

The strategy of Bridge Biotherapeutics Inc. (KOSDAQ:288330) to translate first-in-class molecules discovered in Asia resonated with investors as the company raised W42 billion ($35.8 million) through the sale of 700,000 shares at W60,000 per share in an IPO on KOSDAQ

Read the full 667 word article

User Sign In